U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07077369) titled 'WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy' on July 13.
Brief Summary: urgical treatment represents a critical approach for HCC patients to achieve long-term survival, primarily including hepatectomy and liver transplantation. With the increasing implementation of HCC screening in China, the proportion of patients eligible for curative-intent surgical resection or ablation has risen annually. However, the 5-year tumor recurrence and metastasis rate post-surgery remains as high as 50%-70%. Postoperative adjuvant therapy has thus become essential to reduce the risk of recurrence...